NONMEM Users Network Archive

Hosted by Cognigen

Post-doctoral Fellowship at Astrazeneca - Machine Learning / AI / Pharmacometrics

From: Penland, Chris <Chris.Penland>
Date: Fri, 26 Oct 2018 17:44:32 +0000

Please see the post-doc posting below and get in touch or forward to others=
 who may be interested.

Machine Learning applied to AstraZeneca's Cardiovascular Outcome Trials to =
Predict Individual Cardiovascular & Renal Outcomes

We're currently looking for talented scientists to join our innovative acad=
emic-style Postdoc. From our centre in Gaithersburg, US, you'll be in a glo=
bal pharmaceutical environment, contributing to live projects right from th=
e start. You'll take part in a comprehensive training programme, including =
a focus on drug discovery and development, given access to our existing Pos=
tdoctoral research, and inspired to pursue your own independent research in=
 state of the art laboratories. It's a newly expanding programme spanning a=
 range of therapeutic areas across a wide range of disciplines.

What's more, you'll have the support of a leading academic advisor, who'll =
provide you with the guidance and knowledge you'll need to develop your car=
eer. This is an exciting area that hasn't been explored to its full potenti=
al, making this an opportunity to make a real difference to the future of m=
edical science.

As a world leader in cardiovascular, renal and metabolic medicines, we're a=
lways working on innovative new drugs that will change lives across the glo=
be. To make that happen, we employ a small molecule and new modalities rese=
arch and development strategy with three priorities: heart failure, diabete=
s and chronic kidney disease. You'll focus your efforts on making real prog=
ress toward slowing, stopping or curing some of the most aggressive disease=
s that face humanity today.

We'll use artificial intelligence tools and computational modelling to pred=
ict individual long-term risk of major CV events (MACE) and renal disease b=
ased on patient characteristics and short-term biomarker changes in a very =
large combined database of AstraZeneca's cardiovascular outcomes trials (pa=
tient-level data for ~180 000 individuals). This will facilitate treatment =
selection for patients with diabetes and cardiovascular disease by identify=
ing characteristics that predict therapeutic response or non-response to di=
fferent drug classes, inform patient selection and outcome definitions for =
future CV and renal outcomes trials, and characterize disease progression o=
ver time

Education and Experience requirements

  * A recent PhD and/or a recent Postdoctoral fellowship in a quantitativ=
e discipline (engineering, pharmacology, computational biology, applied mat=
h, or related) with productivity demonstrated by scientific publications an=
d conference presentations.
  * Interest in applying quantitative tools to solve clinically-meaningfu=
l problems


  * Working knowledge of biology and physiology; experience working with =
clinical data a plus

Skills and Capabilities required:

  * Proficiency and hands-on experience with data analysis, machine learn=
ing, and/or computational modelling in R or similar software
  * Ability to communicate technical material to a broad audience

This is a 3 year programme. 2 years will be a Fixed Term Contract, with a =
1 year extension which will be merit based. The role will be based in Gait=
hersburg, US with a competitive salary on offer. To apply for this position=
, please click the apply link below.

Advert opening date - 11th October 2018 / Advert closing date - 22nd Novemb=
er 2018

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that =
focuses on the discovery, development and commercialisation of prescription=
 medicines for some of the world's most serious diseases. But we're more th=
an one of the world's leading pharmaceutical companies. At AstraZeneca, we'=
re proud to have a unique workplace culture that inspires innovation and co=
llaboration. Here, employees are empowered to express diverse perspectives =
- and are made to feel valued, energised and rewarded for their ideas and c=

AstraZeneca is an equal opportunity employer. AstraZeneca will consider all=
 qualified applicants for employment without discrimination on grounds of d=
isability, gender or gender orientation, pregnancy or maternity leave statu=
s, race or national or ethnic origin, age, religion or belief, gender ident=
ity or re-assignment, marital or civil partnership status, protected vetera=
n status (if applicable) or any other characteristic protected by law.

If you share our passion for scientific excellence, find out more at; https=

Chris Penland, PhD
Director, Quantitative Clinical Pharmacology

IMED Biotech Unit | Early Clinical Development
35 Gatehouse Dr, Waltham, MA USA 02451
T: +1 781 839 4618 M: +1 617 275 3769

Please consider the environment before printing this e-mail


Confidentiality Notice: This message is private and may contain confidentia=
l and proprietary information. If you have received this message in error, =
please notify us and remove it from your system and note that you must not =
copy, distribute or take any action in reliance on it. Any unauthorized use=
 or disclosure of the contents of this message is not permitted and may be =

Received on Fri Oct 26 2018 - 13:44:32 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: